Beam Therapeutics (MEX:BEAM) Other Operating Expense: MXN-0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BEAM Beam Therapeutics Inc MEX:BEAM
68 GF Score
Price MXN655.00
GF Value MXN598.99
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Other Operating Expense?

Beam Therapeutics MEX:BEAM 68 Other Operating Expense is MXN-0 Mil as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 68/100 and a GF Value™ of MXN598.99 (Fairly Valued). The stock has 4 warning signs investors should review.

Beam Therapeutics's Other Operating Expense for the three months ended in Mar. 2026 was MXN0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-0 Mil.

Beam Therapeutics's quarterly Other Operating Expense declined from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN-0 Mil) but then increased from Dec. 2025 (MXN-0 Mil) to Mar. 2026 (MXN0 Mil).

Beam Therapeutics's annual Other Operating Expense increased from Dec. 2023 (MXN-0 Mil) to Dec. 2024 (MXN-0 Mil) and increased from Dec. 2024 (MXN-0 Mil) to Dec. 2025 (MXN0 Mil).

Beam Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Other Operating Expense Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only -0.00 -0.00 -0.00 -0.00 0.00

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
MEX:BEAM
68GF Score
Beam Therapeutics Inc MEX:BEAM
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of MXN-0 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Other Operating Expense of MXN-0 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Other Operating Expense too high?
Beam Therapeutics' current Other Operating Expense is MXN-0 Mil. Overall, Beam Therapeutics has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Other Operating Expense compare to ELVN and IDYA?
Beam Therapeutics' Other Operating Expense of MXN-0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Other Operating Expense is MXN-0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN598.99, compared to a current price of MXN655.00 — trading 9.4% above its estimated fair value. The current Other Operating Expense is MXN-0 Mil. Beam Therapeutics' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Other Operating Expense is MXN-0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN655.00 is trading 9.4% above its estimated GF Value™ of MXN598.99. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Other Operating Expense: MXN-0 Mil
  • GF Value™: MXN598.99 vs. price of MXN655.00 (9.4% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
68GF Score

Get the complete analysis for MEX:BEAM

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN655.00
Price
MXN598.99
GF Value